BACKGROUND: Chromodomain helicase DNA binding protein 5 (CHD5) is a family member of chromatin remodeling factors. The epigenetic silencing mechanisms of CHD5 in colorectal cancer have not been well studied. METHODS: Here we analyzed CHD5 methylation and mRNA expression in vitro and in clinical samples from African American patients. DNA and RNA were isolated from formalin fixed paraffin embedded (FFPE) colon tissues. DNA was tested for methylation using methylation-specific polymerase chain reation (PCR) and bisulfite sequencing. RNA was used for mRNA quantification using qRT-PCR. The RKO cell line was treated with 5-Aza-dC and SAHA. RKO cells were also stably transfected with a CHD5-expressing vector. The transcriptional activity was studied in the 1 kb upstream region of the CHD5 promoter using the dual reporter assay. We performed cell proliferation, migration, and invasion assays using the RKO cell line. RESULTS: In most adenoma samples, CHD5 expression was not detected in contrast to normal tissues. In RKO cells, CHD5 silencing was associated with DNA methylation and repressive histone modifications. CHD5 expression was restored after treatment with 5-Aza-dC and SAHA. CHD5 reactivation reduced cell proliferation, migration, and invasion. The reporter assay indicated that the main regulatory region of the CHD5 promoter is encompassed in the -489 to -823 region with important transcriptional regulatory sites (TCF/LEF, SP1, and AP-2). CONCLUSIONS: The CHD5 gene is repressed in all types of adenomas, either epigenetically or by chromosomal deletion. CHD5 activity is regulated by DNA methylation and repressive histone modifications. CHD5 likely acts as a tumor-suppressor gene in early colorectal carcinogenesis.
BACKGROUND:Chromodomain helicase DNA binding protein 5 (CHD5) is a family member of chromatin remodeling factors. The epigenetic silencing mechanisms of CHD5 in colorectal cancer have not been well studied. METHODS: Here we analyzed CHD5 methylation and mRNA expression in vitro and in clinical samples from African American patients. DNA and RNA were isolated from formalin fixed paraffin embedded (FFPE) colon tissues. DNA was tested for methylation using methylation-specific polymerase chain reation (PCR) and bisulfite sequencing. RNA was used for mRNA quantification using qRT-PCR. The RKO cell line was treated with 5-Aza-dC and SAHA. RKO cells were also stably transfected with a CHD5-expressing vector. The transcriptional activity was studied in the 1 kb upstream region of the CHD5 promoter using the dual reporter assay. We performed cell proliferation, migration, and invasion assays using the RKO cell line. RESULTS: In most adenoma samples, CHD5 expression was not detected in contrast to normal tissues. In RKO cells, CHD5 silencing was associated with DNA methylation and repressive histone modifications. CHD5 expression was restored after treatment with 5-Aza-dC and SAHA. CHD5 reactivation reduced cell proliferation, migration, and invasion. The reporter assay indicated that the main regulatory region of the CHD5 promoter is encompassed in the -489 to -823 region with important transcriptional regulatory sites (TCF/LEF, SP1, and AP-2). CONCLUSIONS: The CHD5 gene is repressed in all types of adenomas, either epigenetically or by chromosomal deletion. CHD5 activity is regulated by DNA methylation and repressive histone modifications. CHD5 likely acts as a tumor-suppressor gene in early colorectal carcinogenesis.
Authors: A Formosa; A M Lena; E K Markert; S Cortelli; R Miano; A Mauriello; N Croce; J Vandesompele; P Mestdagh; E Finazzi-Agrò; A J Levine; G Melino; S Bernardini; E Candi Journal: Oncogene Date: 2012-02-06 Impact factor: 9.867
Authors: J Roose; M Molenaar; J Peterson; J Hurenkamp; H Brantjes; P Moerer; M van de Wetering; O Destrée; H Clevers Journal: Nature Date: 1998-10-08 Impact factor: 49.962
Authors: Marieke Aarts; Hilde Dannenberg; Ronald J deLeeuw; Francien H van Nederveen; Albert A Verhofstad; J W Lenders; Winand N M Dinjens; Ernst Jan M Speel; Wan L Lam; Ronald R de Krijger Journal: Genes Chromosomes Cancer Date: 2006-01 Impact factor: 5.006
Authors: Peter S White; Patricia M Thompson; Takahiro Gotoh; Erin R Okawa; Jun Igarashi; Marleen Kok; Cynthia Winter; Simon G Gregory; Michael D Hogarty; John M Maris; Garrett M Brodeur Journal: Oncogene Date: 2005-04-14 Impact factor: 9.867
Authors: R A Cavallo; R T Cox; M M Moline; J Roose; G A Polevoy; H Clevers; M Peifer; A Bejsovec Journal: Nature Date: 1998-10-08 Impact factor: 49.962
Authors: Gerwin Heller; Valerie N Babinsky; Barbara Ziegler; Marlene Weinzierl; Christian Noll; Corinna Altenberger; Leonhard Müllauer; Gerhard Dekan; Yuliya Grin; György Lang; Adelheid End-Pfützenreuter; Irene Steiner; Sonja Zehetmayer; Balazs Döme; Britt-Madeleine Arns; Kwun M Fong; Casey M Wright; Ian A Yang; Walter Klepetko; Martin Posch; Christoph C Zielinski; Sabine Zöchbauer-Müller Journal: Carcinogenesis Date: 2012-11-19 Impact factor: 4.944
Authors: Rosa M Xicola; Zarko Manojlovic; Gaius J Augustus; Sonia S Kupfer; Rajyasree Emmadi; Victoria Alagiozian-Angelova; Tim Triche; Bodour Salhia; John Carpten; Xavier Llor; Nathan A Ellis Journal: Carcinogenesis Date: 2018-12-13 Impact factor: 4.944
Authors: Hassan Ashktorab; Mohammad Daremipouran; Joe Devaney; Sudhir Varma; Hamed Rahi; Edward Lee; Babak Shokrani; Russell Schwartz; Michael L Nickerson; Hassan Brim Journal: Cancer Date: 2014-09-23 Impact factor: 6.860